Cole has more than 20 years of pharmaceutical business development experience and is currently the chief business officer and head of corporate development at Jounce Therapeutics.
Prior to Jounce Therapeutics, Cole served as chief business officer at ARIAD Pharmaceuticals from 2014 to 2017 and was previously at Shire Pharmaceuticals as senior vice president, Strategic Planning and Program Management from 2012 to 2014, Global Franchise Leader from 2009 to 2012, and head of Business Development for Shire's rare disease business from 2007 to 2009.
Cole holds an AB from Harvard University and an MBA from the Wharton School at the University of Pennsylvania.
Catabasis' lead programme is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne.
Soligenix announces appointment of Jonathan Guarino as SVP and CFO
ORIC Pharmaceuticals names new chief financial officer
Oncternal Appoints Kaufmann as Chief Scientific Officer, Bilinsky as Chief Business Officer
Conversa Health appoints Cameron Ough as chief technology officer
Beactica Therapeutics names new head of Preclinical Development and new directors
Terveystalo appoints Ilkka Laurila as interim CEO
Cerevel Therapeutics Names Coles as Chief Executive Officer
Genor Biopharma Named Jack Hu as Chief Financial Officer and Chief Strategy Officer
Aprecia names new vice president of Business Development and Alliance Management
Bolt Biotherapeutics names new chief executive officer and director